Deal Watch: Nanotech Formulations Of Doxorubicin Highlight Recent Deal-Making
Executive Summary
France’s BioAlliance adds to its oncology portfolio through an all-equity merger with Topotarget; NanoSmart and NanoValent team up on an ovarian cancer program; Mylan licenses two respiratory therapies from Prosonix; and Actavis adds to its specialty generics portfolio with products from Akorn.